Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4Phase 3 2

Status

Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Melanoma 4Uveal Melanoma 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × lifileucel × Clear all
NCT05607095 2026-05-28

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
30 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT05176470 2026-02-24

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Ohio State University Comprehensive Cancer Center

Phase 1 Active not recruiting
2 enrolled
Dermatologic

Melanoma

NCT05640193 2025-09-12

A Study of LN-144 in People With Metastatic Melanoma to the Brain

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
10 enrolled
Dermatologic

Melanoma

NCT06190249 2025-06-05

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Case Comprehensive Cancer Center

Phase 1 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡